

DAFTAR PUSTAKA

- Panduan penatalaksanaan kanker 2020. Perhimpunan ahli bedah onkologi Indonesia. 2020. Hal:1
- Sampepajung D. Kanker Payudara di Indonesia, Masalah dan Penanggulangannya. Naskah Pidato pada Upacara Pengukuhan sebagai Guru Besar Bidang Ilmu Bedah onkologi Fakultas Kedokteran Universitas Hasanuddin, Makassar, 27 Desember 2010
- Gong, C., Yao, H., Liu, Q., Chen, J., Shi, J., Su, F. & Song, E. 2010. Markers of tumor-initiating cells predict chemoresistance in breast cancer. *Plos one*, 5, e15630.
- Hicklin DJ, Ellis LM. Interactions of VEGF ligands and VEGF Receptors. *J Clin Oncol*. 2005; 23; p: 1011-27.
- Lee, A., Lim, W., Moon, B. I., Paik, N. S., Koh, S. H. & Song, J. Y. 2011. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline and taxane based chemotherapy. *Journal of breast cancer*, 14, 283-8.
- William J. Gradishar, Benjamin O. Anderson, dkk . (2020). Breast cancer. *NAtional Comprehensive Cancer Network*
- Liu, Y., Du, F., Chen, W., Yao, M., Lv, K. & Fu, P. 2013. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. *Experimental cell research*, 319, 3140-9.
- Wilson, T., Longley, D. & Johnston, P. 2006. Chemoresistance in solid

tumours. *Annals of oncology*, 17, 315-24.

Gao Z hua, Li C xin, Liu M, Jiang J yuan. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. *BMC Cancer* [Internet]. 2020 Dec 1 [cited 2022 Nov 11];20(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/33238978/>

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. *Int J cancer* [Internet]. 2021 Aug 15 [cited 2022 Nov 11];149(4):778–89. Available from: <https://pubmed.ncbi.nlm.nih.gov/33818764/>

Zgura A, Galesa L, Bratila E, Anghel R. Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. *Maedica (Buchar)* [Internet]. 2018 [cited 2022 Nov 11];13(4):317. Available from: <https://pubmed.ncbi.nlm.nih.gov/30774731/>

Ginter PS, Idress R, D’Alfonso TM, Fineberg S, Jaffer S, Sattar AK, et al. Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. *Mod Pathol* [Internet]. 2021 Apr 1 [cited 2022 Nov 11];34(4):701–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/33077923/>

Oluogun WA, Adedokun KA, Oyenike MA, Adeyeba OA. Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study. *Int J Health Sci (Qassim)*. 2019;13(4):3–9.

Lundgren C, Bendahl PO, Ekholm M, Fernö M, Forsare C, Krüger U, et al.

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. *Breast Cancer Res* [Internet]. 2020 Dec 1 [cited 2022 Nov 11];22(1):1–14. Available from: <https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01364-w>

I Gede Aditya Krishna Santhi, I Nengah Wiadnyana Steven Christian, I Gede Raka Widiana, Hubungan antara TIL (*Tumor Infiltrating Lymphocyte*) dan MAI (*Mitotic Activity Index*) dengan kejadian metastase kelenjar getah bening (KGB) aksila pada operable breast cancer di RSUP Sanglah, Denpasar, *Intisari Sains Medis* 2019, Volume 10, Number 2: 465-470

Engstrom, M. et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast cancer research and treatment*, 140. 2013. P. 463-34.

Eisenhauer E. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1,1). *European journal of cancer*, 45. 2009. P.228-47.

Yao et al. 2011 HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. *Annals of Oncology*, 22.p.1326-31.

Edward Chu, M. V. (2019). *Cancer Chemotherapy Drug Manual*. United State of America: Jones & Bartlett Learning.

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, et al. The tale of TILs in breast cancer: A report from The International Immunology Biomarker Working Group. *NPJ breast cancer* [Internet]. 2021

Dec 1 [cited 2022 Nov 11];7(1). Available from:
<https://pubmed.ncbi.nlm.nih.gov/34853355/>

Yuka Asano et al, 2018, Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. *ANTICANCER RESEARCH* 38: 2311-2321

Panduan Tatalaksana Kanker Payudara, PERABOI, Edisi 2023. Hal 1

Aldo Giovanni, Mg. Irsan Saleh, Nur Qodir, Mulawan Umar, 2019 Respon Kemoterapi Neoadjuvan Terhadap Lanjutan Lokal Kanker Payudara Di Rumah Sakit DR Mohammad Hoesin Palembang, *Sriwijaya Journal Of Medicine*.

Alam, A. (2018) Chemotherapy Treatment and Strategy Schemes: A Review, *Open Access Journal of Toxicology*,2(5). Available at:<https://doi.org/10.19080/oajt.2018.02.555600>.

Diana D, Kusmardi (2020) Tumor infiltrating Lymphocytes dan Peranannya pada Karsinoma Payudara, *Maj Pathol Indonesia*. 29(1),pp.30-40.

Yan Wisnu Prajoko (2021). *Dasar Dasar Immunologi Tumor*, Airlangga University Press. hal 133-151

Hee Jin Lee, Jin Young Seo, Jin Hee Ahn, Gyungyub Gong 2013 Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients, *Journal of Breast Cancer*, <http://dx.doi.org/10.4048/jbc.2013.16.1.32>

Ke Wang, Jianjun Xu, Tao Zhang, and Xue, 2016, Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and

survival outcome: A meta-analysis, *Oncotarget*, Vol. 7, No. 28